Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) – Research analysts at Zacks Investment Research raised their FY2017 earnings per share (EPS) estimates for shares of Can-Fite BioPharma in a report released on Wednesday. Zacks Investment Research analyst G. Zeng now forecasts that the biotechnology company will post earnings per share of ($0.59) for the year, up from their prior estimate of ($0.62).
A number of other analysts also recently issued reports on CANF. HC Wainwright set a $6.00 price objective on shares of Can-Fite BioPharma and gave the company a “buy” rating in a report on Thursday, August 10th. Maxim Group began coverage on shares of Can-Fite BioPharma in a report on Friday, August 11th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, ValuEngine downgraded shares of Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a report on Thursday, September 7th.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/12/06/zacks-investment-research-equities-analysts-increase-earnings-estimates-for-can-fite-biopharma-ltd-canf.html.
Can-Fite BioPharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can-Fite BioPharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.